描述：
HCC-1 (Hemofiltrate CC Chemokine-1) was originally isolated from the hemofiltrate of
human patients with chronic renal failure. It belongs to the CC chemokine superfamily and
has been designated CCL14a. HCC-1/CCL14a cDNA encodes a 93 amino acid (aa) residue
precursor with a 19 aa signal peptide that is cleaved to form the 74 aa secreted protein
(aa 20-93). By alternative splicing, a second longer isoform named HCC-3/CCL14b, which
includes sequences from exon 3, also exists. HCC-1/CCL14a is expressed constitutively in
various normal tissues including spleen, liver, muscle, gut and bone marrow. It circulates at
nanomolar concentrations in human plasma. Different posttranslationally modified HCC-1/
CCL14a, including O-glycosylated and N-terminally truncated variants of HCC-1/CCL14a, have
been identified. Whereas the 74 aa peptide is a weak CCR1 agonist, the proteolytically
processed, truncated HCC-1/CCL14a (aa 28 93) is a highly potent agonist of CCR1, CCR5 and
to a lesser extent, CCR3. HCC-1/CCL14a (aa 28-93) promotes chemotaxis of T lymphocytes,
monocytes and eosinophils, and inhibits infection of Mtropic human immunodeficiency virus
type 1. Activation of the HCC-1/CCL14a precursor to active peptide is mediated by the
urokinase type plasminogen activator or plasmin.
原厂资料：
HCC-1 (Hemofiltrate CC Chemokine-1) was originally isolated from the hemofiltrate of
human patients with chronic renal failure. It belongs to the CC chemokine superfamily and
has been designated CCL14a. HCC-1/CCL14a cDNA encodes a 93 amino acid (aa) residue
precursor with a 19 aa signal peptide that is cleaved to form the 74 aa secreted protein
(aa 20-93). By alternative splicing, a second longer isoform named HCC-3/CCL14b, which
includes sequences from exon 3, also exists. HCC-1/CCL14a is expressed constitutively in
various normal tissues including spleen, liver, muscle, gut and bone marrow. It circulates at
nanomolar concentrations in human plasma. Different posttranslationally modified HCC-1/
CCL14a, including O-glycosylated and N-terminally truncated variants of HCC-1/CCL14a, have
been identified. Whereas the 74 aa peptide is a weak CCR1 agonist, the proteolytically
processed, truncated HCC-1/CCL14a (aa 28 93) is a highly potent agonist of CCR1, CCR5 and
to a lesser extent, CCR3. HCC-1/CCL14a (aa 28-93) promotes chemotaxis of T lymphocytes,
monocytes and eosinophils, and inhibits infection of Mtropic human immunodeficiency virus
type 1. Activation of the HCC-1/CCL14a precursor to active peptide is mediated by the
urokinase type plasminogen activator or plasmin.
京公网安备11010802025653 版权所有：北京逸优科技有限公司
